RedHill closes $20M public offering to prep commercialization of new drug
RedHill Biopharma (Nasdaq: RDHL) just closed on a $20 million public offering to fund the commercial launch of its drug, Talicia, and fund Phase 3 studies of two other candidates.
The public offering opened Dec. 4 for nearly 2.9 million American depositary shares, at a price of $7 per share. Each ADS represents 10 ordinary shares of RedHill. The company has also granted the underwriters a 30-day option to purchase up to 428,571 additional shares at the public offering price.
Talicia is a treatment…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Seth Gulledge Source Type: news